SCHEMBL20142219

SCHEMBL20142219

Cc1cc(OCc2ccccc2)c(Br)cc1Cc1ccc2c(c1)C(=O)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.40
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
PTPN1 P18031 3/20 0.39
PTGER1 P34995 3/20 0.39
CYP1A2 P05177 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
BRD4 O60885 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
CCR5 P51681 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139491 0.84 HTR2A (0.45) FFAR4HTR2AHTR2CRXRARXRB
SCHEMBL7632432 0.82 TDP1 (0.47) FFAR4MAOAMAOBHTR2AHTR2C
SCHEMBL3229125 0.80 MAPT (0.45) FFAR4MAOBHTR2AHTR2CPTGER1
SCHEMBL20139641 0.79 SLC5A1 (0.40) HTR2AKDM4E
SCHEMBL3215337 0.79 MAPT (0.42) FFAR4HTR2AHTR2CRXRARXRB
SCHEMBL3222581 0.77 ABCB1 (0.52) MAOBRAB9A
SCHEMBL21551803 0.77 MAOB (0.50) MAOAMAOBHTR2AHTR2CRAB9A
SCHEMBL20140087 0.77 MAPK1 (0.39) HTR2AHTR2CKDM4E
SCHEMBL1539223 0.76 SLC5A2 (0.43) MAOAMAOBRAB9ASMN1; SMN2
SCHEMBL3223812 0.76 SLC6A2 (0.41) FFAR4HTR2AHTR2CRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 FFAR4 565/4885MAOA 3829/4885MAOB 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.